PTC Therapeutics (NASDAQ:PTCT) Q2 results: Revenues: $85.5M (+24%); Translarna sales: $57.8M (+21%).
Net loss: ($41.8M).
U.S. marketing application for risdiplam for SMA Types 1,2&3 to be filed later this year followed by an application in Europe in H1 2020.
2019 guidance: DMD product sales: $285M – 305M (unch).
Previously: PTC Therapeutics EPS misses by $0.17, beats on revenue (Aug. 6)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.